EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials

Andrea Blasco, Sara López-Tarruella iD, Ander Urruticoechea, Eva Carrasco, Gonzalo Spera, Miguel Martín iD, Begoña Bermejo, Linnea Chap, Manuel Ruiz-Borrego, John Crown, Jose A García-Saenz, Arlene Chan und 6 weitere

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf263 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Andrea Blasco und 17 weiteren Autor:innen. Beteiligte Einrichtung: GEICAM, Spanish Breast Cancer Group, San Sebastián de los Reyes 28703, Spain. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GEICAM Spanish Breast Cancer Group.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance and Objective Several definitions of efficacy endpoints have been proposed for clinical trials in early breast cancer (EBC). Invasive disease-free survival (IDFS) and other endpoints have been used as surrogates for overall survival (OS) in adjuvant trials. The aim was to evaluate these endpoints in a comparative way in a large cohort of patients to assess whether they are appropriate surrogates for OS. Participants and Design Individual patient data from 8 phase III randomized adjuvant chemotherapy (CT) trials for EBC were analyzed. Trial-level surrogacy analyses were conducted using weighted least squares regression to assess the association between treatment effects on surrogates at different time points—IDFS and other defined endpoints (by STEEP v2.0)—and OS. Correlation between the log hazard ratio (HR) of the endpoints and OS were quantified using R2 values. Preplanned subgroup analyses by tumor subtype were also performed. Results Results censoring at 5 years and at longer follow-up (median: 9.6 years) were similar. HR of IDFS and invasive BC-free survival (IBCFS) at 5 years showed a R2 > 0.7 relative to HR of OS. All other surrogates revealed correlations with R2 > 0.5. For patients with hormone receptor-positive/HER2-negative intermediate/high-risk tumors, correlation showed higher R2 for IDFS (R2 = 0.89; 95% confidence interval [CI] = [0.80-0.98]) and IBCFS (R2 = 0.84; 95% CI = [0.71-0.97]) than distant-recurrence endpoints, while for those with triple negative tumors the highest correlation was seen with distant disease-free survival (R2 = 0.86; 95% CI = [0.75-0.98]). Conclusions and Relevance Although all studied endpoints are appropriate surrogates for OS when evaluating CT-based adjuvant interventions, investigators should consider the BC subtype to select the primary endpoint. Trial registration number: ClinTrials.gov: GEICAM/9805: NCT00121992; GEICAM/9906: NCT00129922; GEICAM/2003-02: NCT00129389; GEICAM/2003-10: NCT00129935; CIBOMA/2004-01_GEICAM/2003-11: NCT00130533; BCIRG 001: NCT00688740; BCIRG 005: NCT00312208 and BCIRG 006: NCT00021255.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleChemotherapy, AdjuvantMiddle AgedDisease-Free SurvivalClinical Trials, Phase III as TopicAdultRandomized Controlled Trials as TopicAged

Stichwörter der Autor:innen

adjuvant chemotherapybreast cancerearly-stagesurrogate endpoint

Autor:innen und Institutionen

  • GEICAM, Spanish Breast Cancer Group, San Sebastián de los Reyes 28703, Spain.
  • Hospital Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Universidad Complutense, Madrid 28007, Spain.
  • Centro de Investigación Biomédica en Red en Oncología (CIBERONC) y en Epidemiología y Salud Pública (CIBERESP), Madrid 28222, Spain.
  • OSI Donostialdea-Osakidetza, BioGipuzkoa, Donostia, Guipuzcoa 20014, Spain.
  • Medical Affairs Department, Translational Research in Oncology (TRIO), Montevideo 11300, Uruguay.
  • Hospital Clínico Universitario de Valencia, INCLIVA, Universidad de Medicina de Valencia, Valencia 46010, Spain.

ORCID-Profile: Sara López-Tarruella, Miguel Martín

Förderung

  • GEICAM Spanish Breast Cancer Group

Zitieren

APA

Blasco, A., López-Tarruella, S., Urruticoechea, A., Carrasco, E., Spera, G., Martín, M., Bermejo, B., Chap, L., Ruiz-Borrego, M., Crown, J., García-Saenz, J. A., Chan, A., Guerrero-Zotano, Á., Semiglazov, V., Calvo, L., Pienkowski, T., Herranz, J., & Slamon, D. (2025). Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials. The Oncologist. https://doi.org/10.1093/oncolo/oyaf263

Vancouver

Blasco A, López-Tarruella S, Urruticoechea A, Carrasco E, Spera G, Martín M, et al. Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials. The Oncologist. 2025. doi:10.1093/oncolo/oyaf263

BibTeX
@article{Blasco2025,
  author = {Blasco, Andrea and López-Tarruella, Sara and Urruticoechea, Ander and Carrasco, Eva and Spera, Gonzalo and Martín, Miguel and Bermejo, Begoña and Chap, Linnea and Ruiz-Borrego, Manuel and Crown, John and García-Saenz, Jose A and Chan, Arlene and Guerrero-Zotano, Ángel and Semiglazov, Vladimir and Calvo, Lourdes and Pienkowski, Tadeusz and Herranz, Jesús and Slamon, Dennis},
  title = {Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf263}
}
Kostenlos starten →